AC Immune (ACIU) News Today $2.94 +0.02 (+0.68%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period AC Immune (NASDAQ:ACIU) Stock Passes Below 200-Day Moving Average - Here's What HappenedAC Immune (NASDAQ:ACIU) Share Price Passes Below 200 Day Moving Average - Time to Sell?December 18 at 4:33 AM | marketbeat.comAC Immune Announces Promising Safety Data for Down Syndrome TherapyDecember 11, 2024 | markets.businessinsider.comAC Immune Reports Encouraging Interim Safety Data From ABATE Study Of ACI-24.060 In Down SyndromeDecember 10, 2024 | markets.businessinsider.comAC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndromeDecember 10, 2024 | markets.businessinsider.comAC Immune Q3 2024: Strong Progress and Financial TurnaroundNovember 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)November 19, 2024 | markets.businessinsider.comAC Immune SA: Promising Vaccine Developments and Strategic Partnerships Drive Buy RatingNovember 18, 2024 | markets.businessinsider.comPromising Interim Data and Safety Profile Justify Buy Rating for AC Immune’s ACI-7104.056 Vaccine TrialNovember 16, 2024 | markets.businessinsider.comAC Immune (NASDAQ:ACIU) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $16.00 price objective on shares of AC Immune in a research report on Friday.November 15, 2024 | marketbeat.comAC Immune reports interim results from Phase 2 trial of ACI-7104.056November 15, 2024 | markets.businessinsider.comAC Immune’s Promising Trial Results for Parkinson’s TherapyNovember 15, 2024 | markets.businessinsider.comAC Immune SA (NASDAQ:ACIU) Short Interest Up 23.5% in OctoberAC Immune SA (NASDAQ:ACIU - Get Free Report) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 984,500 shares, a growth of 23.5% from the October 15th total of 796,900 shares. Based on an average daily volume of 92,100 shares, the short-interest ratio is currently 10.7 days. Approximately 1.6% of the shares of the stock are sold short.November 15, 2024 | marketbeat.comAC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's PatientsNovember 14, 2024 | benzinga.comAC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseNovember 14, 2024 | markets.businessinsider.comAC Immune to Present at the Jefferies 2024 London Healthcare ConferenceNovember 14, 2024 | markets.businessinsider.comAC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New EstimatesNovember 9, 2024 | finance.yahoo.comFY2024 EPS Estimates for AC Immune Boosted by HC WainwrightAC Immune SA (NASDAQ:ACIU - Free Report) - Equities research analysts at HC Wainwright upped their FY2024 earnings estimates for shares of AC Immune in a note issued to investors on Wednesday, November 6th. HC Wainwright analyst A. Fein now expects that the company will earn ($0.62) per share forNovember 8, 2024 | marketbeat.comFY2024 EPS Estimates for AC Immune Lifted by Leerink PartnrsAC Immune SA (NASDAQ:ACIU - Free Report) - Equities research analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for shares of AC Immune in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now expects that the company will pNovember 8, 2024 | marketbeat.comAC Immune SA: Promising Pipeline Developments and Robust Financial Health Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comLeerink Partnrs Decreases Earnings Estimates for AC ImmuneAC Immune SA (NASDAQ:ACIU - Free Report) - Leerink Partnrs dropped their FY2027 earnings estimates for AC Immune in a research report issued to clients and investors on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.06 per share forNovember 7, 2024 | marketbeat.comOptimistic Buy Rating on AC Immune Due to Promising Vaccine and Pipeline DevelopmentsNovember 6, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for AC Immune (NASDAQ:ACIU)HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of AC Immune in a research note on Wednesday.November 6, 2024 | marketbeat.comAC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 6, 2024 | finance.yahoo.comAC Immune SA Reports Profitable Q3 2024 ResultsNovember 6, 2024 | markets.businessinsider.comAssenagon Asset Management S.A. Trims Holdings in AC Immune SA (NASDAQ:ACIU)Assenagon Asset Management S.A. decreased its holdings in AC Immune SA (NASDAQ:ACIU - Free Report) by 49.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,880 shares of the company's stock after sellinNovember 3, 2024 | marketbeat.comShort Interest in AC Immune SA (NASDAQ:ACIU) Decreases By 7.4%AC Immune SA (NASDAQ:ACIU - Get Free Report) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 796,900 shares, a decrease of 7.4% from the September 30th total of 860,900 shares. Based on an average daily volume of 118,700 shares, the days-to-cover ratio is currently 6.7 days. Approximately 1.3% of the company's stock are short sold.October 30, 2024 | marketbeat.comAC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%October 29, 2024 | uk.finance.yahoo.comWhat To Expect From AC Immune SA (ACIU) Q3 2024 EarningsOctober 24, 2024 | finance.yahoo.comAC Immune SA (NASDAQ:ACIU) Short Interest Up 12.9% in SeptemberAC Immune SA (NASDAQ:ACIU - Get Free Report) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 860,900 shares, a growth of 12.9% from the September 15th total of 762,400 shares. Based on an average daily trading volume, of 126,600 shares, the days-to-cover ratio is presently 6.8 days. Currently, 1.4% of the company's shares are sold short.October 15, 2024 | marketbeat.comRenaissance Technologies LLC Has $2.60 Million Position in AC Immune SA (NASDAQ:ACIU)Renaissance Technologies LLC raised its stake in AC Immune SA (NASDAQ:ACIU - Free Report) by 26.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 652,079 shares of the company's stock after buying an additional 136,300 shares during the qOctober 2, 2024 | marketbeat.comAC Immune (NASDAQ:ACIU) Downgraded by StockNews.comStockNews.com downgraded AC Immune from a "buy" rating to a "hold" rating in a research note on Tuesday.October 1, 2024 | marketbeat.comBuy Rating Justified: AC Immune SA’s Strategic Advancements in Alzheimer’s Treatment and Strong Financial PositionSeptember 18, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating for AC Immune SA on Promising Alzheimer’s Treatment ProspectsSeptember 18, 2024 | markets.businessinsider.comAC Immune's (ACIU) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of AC Immune in a research report on Wednesday.September 18, 2024 | marketbeat.comAC Immune SA: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's DiseaseSeptember 17, 2024 | finanznachrichten.deAC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic ScanAugust 29, 2024 | marketwatch.comAC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative ConditionsAugust 29, 2024 | markets.businessinsider.comThe past three years for AC Immune (NASDAQ:ACIU) investors has not been profitableAugust 23, 2024 | finance.yahoo.comAssenagon Asset Management S.A. Has $1.76 Million Stock Holdings in AC Immune SA (NASDAQ:ACIU)Assenagon Asset Management S.A. lifted its holdings in shares of AC Immune SA (NASDAQ:ACIU - Free Report) by 294.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 439,730 shares of the company's stock afteAugust 22, 2024 | marketbeat.comAC Immune (NASDAQ:ACIU) Share Price Passes Below Fifty Day Moving Average of $3.84AC Immune (NASDAQ:ACIU) Stock Crosses Below Fifty Day Moving Average of $3.84August 17, 2024 | marketbeat.comCan Your AC Really Make You Sick? Experts Reveal the TruthAugust 15, 2024 | msn.comHC Wainwright Equities Analysts Raise Earnings Estimates for AC Immune SA (NASDAQ:ACIU)AC Immune SA (NASDAQ:ACIU - Free Report) - Stock analysts at HC Wainwright raised their Q3 2024 earnings estimates for AC Immune in a report released on Wednesday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.22) per share for the quarter, up from their pAugust 9, 2024 | marketbeat.comLeerink Partnrs Research Analysts Lower Earnings Estimates for AC Immune SA (NASDAQ:ACIU)AC Immune SA (NASDAQ:ACIU - Free Report) - Stock analysts at Leerink Partnrs dropped their FY2028 earnings estimates for shares of AC Immune in a research note issued on Tuesday, August 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $0.10 per share forAugust 8, 2024 | marketbeat.comBuy Rating on AC Immune SA for Promising Alzheimer’s and Parkinson’s VaccinesAugust 7, 2024 | markets.businessinsider.comAC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAugust 6, 2024 | finance.yahoo.comAC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024July 31, 2024 | globenewswire.comAC Immune SA (NASDAQ:ACIU) Short Interest UpdateAC Immune SA (NASDAQ:ACIU - Get Free Report) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 964,900 shares, a growth of 32.0% from the June 30th total of 731,100 shares. Based on an average daily volume of 830,800 shares, the short-interest ratio is currently 1.2 days. Approximately 1.7% of the company's stock are short sold.July 27, 2024 | marketbeat.comAC Immune (NASDAQ:ACIU) Stock Passes Below 50-Day Moving Average of $3.92AC Immune (NASDAQ:ACIU) Shares Cross Below 50 Day Moving Average of $3.92July 26, 2024 | marketbeat.comAC Immune SA: AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's DiseaseJuly 25, 2024 | finanznachrichten.deAC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s DiseaseJuly 25, 2024 | markets.businessinsider.com Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. ACIU Media Mentions By Week ACIU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACIU News Sentiment▼1.410.69▲Average Medical News Sentiment ACIU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACIU Articles This Week▼12▲ACIU Articles Average Week Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Rocket Pharmaceuticals News Today Bicycle Therapeutics News Today Avadel Pharmaceuticals News Today Collegium Pharmaceutical News Today Septerna News Today Zymeworks News Today Bicara Therapeutics News Today Gyre Therapeutics News Today Poseida Therapeutics News Today Phibro Animal Health News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACIU) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACIU Stock Alerts